ANNUAL BIOMARKER TESTING
Annual testing patterns for EGFR, ALK, PD-L1, and NGS are summarized by diagnosis year. The table below preserves the diagnosis-year-specific patient counts and testing coverage reported in the current ROOT HEALTH workbook.
Cohort definition: 38,154 patients with NSCLC, excluding stage 0,
who received cancer-directed treatment at Samsung Medical Center.
Data cutoff: September 18, 2026.
Annual Biomarker Testing in NSCLC
Diagnosis year 2008–2026, with overall totals shown in the final row.
| Diagnosis Year | Total NSCLC Patients | EGFR Tested (N) | EGFR Tested (%) | ALK Tested (N) | ALK Tested (%) | PD-L1 Tested (N) | PD-L1 Tested (%) | NGS Tested (N) | NGS Tested (%) |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1,597 | 1,503 | 94.1% | 1,508 | 94.4% | 1,521 | 95.2% | 285 | 17.8% |
| 2025 | 2,227 | 2,043 | 91.7% | 2,021 | 90.7% | 2,064 | 92.7% | 441 | 19.8% |
| 2024 | 1,714 | 1,563 | 91.2% | 1,539 | 89.8% | 1,569 | 91.5% | 371 | 21.6% |
| 2023 | 2,776 | 2,579 | 92.9% | 2,574 | 92.7% | 2,611 | 94.1% | 655 | 23.6% |
| 2022 | 2,652 | 2,462 | 92.8% | 2,473 | 93.3% | 2,503 | 94.4% | 638 | 24.1% |
| 2021 | 2,736 | 2,516 | 92.0% | 2,545 | 93.0% | 2,582 | 94.4% | 628 | 23.0% |
| 2020 | 2,497 | 2,332 | 93.4% | 2,359 | 94.5% | 2,388 | 95.6% | 561 | 22.5% |
| 2019 | 2,240 | 2,082 | 92.9% | 2,084 | 93.0% | 2,119 | 94.6% | 435 | 19.4% |
| 2018 | 2,414 | 2,227 | 92.3% | 2,230 | 92.4% | 1,963 | 81.3% | 428 | 17.7% |
| 2017 | 2,447 | 2,264 | 92.5% | 2,271 | 92.8% | 1,199 | 49.0% | 233 | 9.5% |
| 2016 | 2,188 | 1,979 | 90.4% | 1,970 | 90.0% | 725 | 33.1% | 144 | 6.6% |
| 2015 | 1,701 | 1,483 | 87.2% | 1,459 | 85.8% | 386 | 22.7% | 76 | 4.5% |
| 2014 | 2,059 | 1,786 | 86.7% | 1,755 | 85.2% | 307 | 14.9% | 58 | 2.8% |
| 2013 | 1,929 | 1,478 | 76.6% | 1,471 | 76.3% | 201 | 10.4% | 45 | 2.3% |
| 2012 | 1,583 | 834 | 52.7% | 873 | 55.1% | 127 | 8.0% | 32 | 2.0% |
| 2011 | 1,508 | 814 | 54.0% | 659 | 43.7% | 82 | 5.4% | 24 | 1.6% |
| 2010 | 1,394 | 664 | 47.6% | 436 | 31.3% | 62 | 4.4% | 13 | 0.9% |
| 2009 | 1,261 | 438 | 34.7% | 187 | 14.8% | 50 | 4.0% | 16 | 1.3% |
| 2008 | 1,231 | 318 | 25.8% | 108 | 8.8% | 39 | 3.2% | 14 | 1.1% |
| Total | 38,154 | 31,365 | 82.2% | 30,522 | 80.0% | 22,498 | 59.0% | 5,097 | 13.4% |